• Cy3 NHS Ester (Non-Sulfonated): Product Overview

  2026-10-07

  A source-limited overview of APExBIO’s Cy3 NHS ester (non-sulfonated), covering its documented identity, intended labeling scope, supplier-reported properties, and evidence limitations.

• CB2R, Iron Overload, and Liver Protection

  2026-10-07

  Deng et al. report that cannabinoid receptor 2 (CB2R) activation protects against iron overload-related liver injury through complementary effects on STAT3/hepcidin signaling in hepatocytes and Nrf2/FPN1 signaling in Kupffer cells. The findings identify CB2R as a mechanistic regulator of hepatic iron handling, while remaining preclinical and model-dependent.

• AICAR, AMPK, and Metabolic Disease Research

  2026-10-06

  AICAR is widely discussed as a pharmacological probe of AMPK-linked energy metabolism, but its relevance depends on the biological question and the strength of pathway validation. This overview places AICAR in the context of a 2025 study of Lycium barbarum polysaccharide in high-fat-diet-associated skeletal muscle atrophy. The study linked improved muscle and metabolic outcomes to AMPK/PINK1/Parkin-mediated mitophagy, yet it did not test AICAR. The evidence therefore supports AMPK and mitophagy as research targets, not a direct claim that AICAR treats sarcopenic obesity or reproduces the effects of the polysaccharide. Key limitations include model dependence, pathway specificity, incomplete translation to humans, and the distinction between a chemical probe and a therapeutic intervention.

• Protease Inhibition: Evidence From Plant Signaling

  2026-10-06

  A source-grounded overview of protease inhibition research, using a plant stomatal-signaling study to distinguish phenotypic evidence from target-level interpretation and to define the limits of broader screening applications.

• CBD and Orofacial Inflammatory Pain: Study Analysis

  2026-10-05

  Wang et al. examine cannabidiol across sensory, affective, and cognitive dimensions of inflammatory pain in mice, combining behavioral, biochemical, molecular, and fiber-photometry evidence. The study’s main innovation is its integrated view of peripheral CB2-linked and central CB1-linked mechanisms, while its translational relevance remains limited by the preclinical models and behavioral proxies used.

• Open-Platform DLP for 96-Well Hydrogel Printing

  2026-10-05

  Mathis and colleagues present an open-platform digital light printer designed for reproducible 96-well hydrogel fabrication and localized light activation. The study demonstrates plate-scale thickness control, customizable two-dimensional gel patterns, and spatial de-caging of DNA, while defining a practical evidence base for high-throughput biomaterials research rather than biological efficacy or clinical translation.

• Sodium Citrate and the Logic of SERS Evidence

  2026-10-04

  Sodium citrate is often discussed in relation to colloidal stability, chelation, and assay buffering, but its evidentiary role in SERS must be separated from substrate geometry. This article interprets a recent 3D gold nanocluster study through chemical attribution, reproducibility, and application boundaries.

• From PolyA Capture to Translational Insight

  2026-10-03

  A source-grounded perspective on how selective mRNA capture can support mechanistic research in endometrial cancer, using the NSD1–PPARγ–PTEN axis as a case study while keeping evidence, limitations, and product claims distinct.

• CX-4945 (Silmitasertib): CK2 Assay Workflow

  2026-10-02

  Build reproducible CK2 inhibition experiments with CX-4945 (Silmitasertib), from DMSO stock preparation through pathway, apoptosis, cell-cycle, and viral-replication readouts. The workflow connects cancer-biology applications with a recent CIAV host-factor study while clearly separating established findings from practical assay recommendations.

• Z-Ligustilide, PLPP1, and Cisplatin Resistance

  2026-10-01

  This preprint links the activity of Z-ligustilide plus cisplatin to PLPP1-associated phospholipid remodeling, reduced PIP3-AKT signaling, cell-cycle arrest, and apoptosis in cisplatin-resistant lung cancer cells. Its integrated metabolomics, transcriptomics, and functional knockdown design offers a mechanistic hypothesis for overcoming resistance, while the lack of peer review and in vivo validation limits immediate translational conclusions.

• Developmental SSRI Exposure and Mu Opioid Signaling

  2026-10-01

  Cambre’s 2026 dissertation identifies a motivation-specific reward deficit after developmental SSRI exposure in adolescent and adult mice, while reward liking and learning remain comparatively intact. The work further shows that mu opioid receptor antagonism and nucleus accumbens MOR knockdown can improve effortful behavior, whereas additional SSRI treatment and the MOR agonist tianeptine do not.

• FAM83A, Mitochondria, and White Adipocyte Differentiation

  2026-09-30

  The reference study identifies FAM83A as a regulator of white adipocyte differentiation that connects casein kinase 1 activity with mitochondrial maintenance and lipogenesis. Using FITC-ATS-9R to deliver an sgRNA/Cas9 construct in mice, the authors show that Fam83a suppression reduces adipose expansion, disrupts mitochondrial function, and limits lipid droplet formation.

• Pulsed Plasma Degradation of Sulfamonomethoxine

  2026-09-30

  The reference study shows that pulsed plasma discharge can remove Sulfamonomethoxine (SMM) from aqueous solution with first-order kinetics and energy-dependent performance. Its most important practical finding is that chemical degradation did not guarantee detoxification: hydrogen peroxide generated during treatment produced acute toxicity to the green alga Raphidocelis subcapitata.

• Liproxstatin-1 and the Last Mile of Ferroptosis

  2026-09-29

  Ferroptosis research is moving beyond lipid peroxide initiation toward the decisive biology of plasma membrane failure. This thought-leadership analysis positions Liproxstatin-1 as a mechanistic rescue tool for separating oxidative damage from terminal membrane execution, while outlining how translational teams can connect renal injury models with emerging tumor-immune findings without overstating preclinical evidence.

• ICG001 for Wnt/β-Catenin Fibrosis Research

  2026-09-29

  ICG001 is a selective Wnt/β-catenin pathway inhibitor for separating CBP-dependent transcription from broader pathway effects. This workflow translates new evidence linking MMP7, E-cadherin cleavage, β-catenin nuclear translocation, and liver fibrosis into practical cell-based assays while clearly distinguishing hypothesis generation from validated therapy.

3676 records 2/246 page Previous Next 12345 下5页 Last page